
    
      Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced
      hepatocellular carcinoma. No study has evaluated the efficacy and safety of lenvatinib plus
      toripalimab. Thus, the investigators carried out this single-arm, prospective, phase II study
      to find out it.
    
  